Welcome to our dedicated page for Cbdmd news (Ticker: YCBD), a resource for investors and traders seeking the latest updates and insights on Cbdmd stock.
cbdMD, Inc. reports developments in hemp-derived cannabinoid consumer products, including the cbdMD, Paw CBD, Bluebird Botanicals and Herbal Oasis brands.
Company news focuses on CBD product categories, THC-infused social seltzer distribution, clinical and regulatory science initiatives, acquisitions, financial results, liquidity, balance-sheet actions and exchange-listing compliance.
cbdMD (NYSE American: YCBD) reported Q2 FY2026 net sales of $5.6 million, up 19% year-over-year and 12% sequentially, driven by core growth and the Bluebird Botanicals acquisition.
Wholesale sales rose 65%, direct-to-consumer 4%. Operating loss was $0.8 million; net loss to common shareholders was $0.88 million. Working capital reached $5.4 million.
The Bluebird integration is progressing, with positive income in March. cbdMD is building a clinical healthcare channel to serve CMS’s new BEI Medicare pathway for eligible hemp-derived CBD products, aiming to leverage emerging bipartisan hemp legislation and cannabis rescheduling.
cbdMD (NYSE American: YCBD) announced it will host a conference call on Thursday, May 14, 2026 at 4:20 p.m. ET to discuss its March 31, 2026 second quarter financial results and business progress.
Investors can join via phone or webcast, with a replay available through May 14, 2027.
Hawkeye Systems (BGH) announced a Board expansion on May 5, 2026, naming Martin Sumichrast as Chairman and adding Sim Farar, Brad Fleisher, and Ralph Olson; former chairman and CEO Corby Marshall remains on the board.
The company said this follows the appointment of President David Wachsman and signals a shift toward a private equity and merchant banking platform focused initially on crypto, blockchain, and cybersecurity, with planned expansion into other financial services and advanced technology verticals.
cbdMD (NYSE: YCBD) launched a clinical healthcare channel to support physician-supervised use of hemp-derived CBD within select Medicare value-based care models, effective April 1, 2026.
CMS activated the Substance Access Beneficiary Engagement Incentive (BEI) to include eligible hemp-derived cannabinoid products in certain models, and cbdMD highlights OECD toxicology data, an IRB-approved randomized clinical trial, GRAS dossiers, and healthcare-grade supply systems to serve providers.
cbdMD (NYSE American: YCBD) reported a sequential revenue increase and improved liquidity for Q1 FY2026 ended December 31, 2025. Net sales were $5.0 million, up 12% sequentially; working capital rose to $5.4 million and cash to $3.4 million. The company closed a $2.25 million Series C and completed the acquisition of Bluebird Botanicals, including GRAS status for full‑spectrum CBD, with integration underway.
Operating loss was $286,000 and adjusted EBITDA was a $36,000 loss; net loss attributable to common shareholders was $0.32 million (loss of $0.04 per share).
cbdMD (NYSE American: YCBD) will host a conference call to discuss its December 31, 2025 first quarter financial results and business progress.
The call is set for 4:20 p.m. ET on Tuesday, February 17, 2026. Dial-in for USA/Canada is 888-880-3330. A webcast and replay are available through February 17, 2027.
cbdMD (NYSE American: YCBD) expanded distribution for its Herbal Oasis THC-infused social seltzer into Louisiana via an expanded partnership with Morales Beverage Group (MBG). Management expects initial shipments to begin in late February 2026, leveraging MBG’s statewide infrastructure after strong early performance in Texas. The release cites U.S. THC beverage sales of $1.6 billion in 2025 and a projected $3.5 billion by 2030 (Fact MR), and highlights Oasis’s blend of hemp-derived THC, CBD, CBG and adaptogenic mushrooms plus flavor SKUs like Lemon Lift and Mango Bliss.
cbdMD (NYSE American: YCBD) announced an integrated regulatory science and safety program following its January 2026 acquisition of substantially all assets of Bluebird Botanicals. The move combines Bluebird's full-spectrum GRAS dossier with cbdMD's clinical and toxicology data to pursue new GRAS work and stronger regulatory engagement.
Management cites an estimated 10% step in revenue growth from the acquisition and says the program will be executed primarily through internal scientific, quality, and regulatory teams to reduce external consulting costs.
cbdMD (NYSE American: YCBD) announced the closing of its acquisition of substantially all assets of Bluebird Botanicals on January 14, 2026. The transaction was an asset purchase completed using an initial share issuance plus earnout shares, and the company referenced a Form 8-K filed with the SEC on January 13, 2026 for terms. cbdMD said the deal adds an established revenue base, branded consumer loyalty, and a portfolio of patented-process technologies and regulatory compliance documentation. Management expects cost and revenue synergies from consolidated supply chain, manufacturing, and shared services, and said the acquisition supports its goal of achieving positive EBITDA and net income as it broadens product offerings and cross-brand distribution.
cbdMD (NYSE American: YCBD) reported fiscal 2025 results for the year ended September 30, 2025, citing its third consecutive year of operating improvement and steps to strengthen the balance sheet and regain exchange compliance.
Key facts: Net sales $19.19M, gross margin 62%, loss from operations $2.16M (improved vs $3.32M in 2024), net loss to common $4.38M, cash $2.26M, and shareholders' equity ≈ $7.23M. Financing actions include $1.7M Series B (closed Sept 2025), $2.25M Series C (closed Dec 18, 2025), and a $20M equity line of credit (Dec 15, 2025 amendment).
The company said it resolved NYSE American listing deficiencies and noted an audit explanatory paragraph regarding its ability to continue as a going concern.